IL125420A0 - Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines containing said protein - Google Patents

Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines containing said protein

Info

Publication number
IL125420A0
IL125420A0 IL12542097A IL12542097A IL125420A0 IL 125420 A0 IL125420 A0 IL 125420A0 IL 12542097 A IL12542097 A IL 12542097A IL 12542097 A IL12542097 A IL 12542097A IL 125420 A0 IL125420 A0 IL 125420A0
Authority
IL
Israel
Prior art keywords
protein
yeast
expression
group
outer membrane
Prior art date
Application number
IL12542097A
Other languages
English (en)
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of IL125420A0 publication Critical patent/IL125420A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12542097A 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines containing said protein IL125420A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1097296P 1996-02-01 1996-02-01
US2044096P 1996-06-13 1996-06-13
PCT/US1997/001687 WO1997028273A1 (en) 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines

Publications (1)

Publication Number Publication Date
IL125420A0 true IL125420A0 (en) 1999-03-12

Family

ID=26681820

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12542097A IL125420A0 (en) 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines containing said protein

Country Status (9)

Country Link
EP (1) EP0877816A1 (ko)
JP (1) JP2001508758A (ko)
KR (1) KR19990082265A (ko)
AU (1) AU2115897A (ko)
HU (1) HUP9901039A2 (ko)
IL (1) IL125420A0 (ko)
NO (1) NO983474L (ko)
PL (1) PL328096A1 (ko)
WO (1) WO1997028273A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272062A (zh) 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
EP2261351A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP4524816B2 (ja) * 1998-07-06 2010-08-18 東ソー株式会社 Il−6レセプター・il−6直結融合蛋白質
EP1094081B1 (en) * 1998-07-06 2005-09-21 Tosoh Corporation Fused protein with direct bond of il-6-receptor to il-6
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
EP2290083B1 (en) 1999-04-30 2014-08-20 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
EE200100597A (et) 1999-05-13 2003-02-17 American Cyanamid Company Antigeenne kompositsioon kombinatsioonis adjuvantidega ning meetod selle toimetõhususe suurendamiseks
CA2929348A1 (en) * 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
EP1069133A1 (en) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
ATE460484T1 (de) * 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
RU2299906C2 (ru) * 2000-02-28 2007-05-27 Новартис Вэксинс Энд Диагностикс С.Р.Л. Гетерологичная экспрессия белков neisseria
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
JP2006262846A (ja) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk 酵母による2−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた2−デオキシ−シロ−イノソース
KR100919704B1 (ko) * 2007-09-12 2009-10-06 한국생명공학연구원 효모에서 재조합단백질을 고효율로 분비발현시키는 방법
JP2011116658A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
CN106146679B (zh) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 一种纯化细菌荚膜多糖的方法
CA3010288A1 (en) * 2015-12-30 2017-07-06 Dsm Ip Assets B.V. Partial enzymatic hydrolysis of triacylglycerols
SG11202111468SA (en) * 2019-04-17 2021-11-29 Impossible Foods Inc Materials and methods for protein production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

Also Published As

Publication number Publication date
AU2115897A (en) 1997-08-22
WO1997028273A1 (en) 1997-08-07
NO983474L (no) 1998-09-30
PL328096A1 (en) 1999-01-04
NO983474D0 (no) 1998-07-28
HUP9901039A2 (hu) 1999-07-28
KR19990082265A (ko) 1999-11-25
JP2001508758A (ja) 2001-07-03
EP0877816A1 (en) 1998-11-18

Similar Documents

Publication Publication Date Title
IL125420A0 (en) Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines containing said protein
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
PL312712A1 (en) High level expression, purification and repeated creasing of group b(porynowe?) proteins of outer membrane of neisseria meningitidis
HUP9903169A3 (en) Low pathogenicity prrs live virus vaccines and methods of preparation thereof
AU4803196A (en) Recombinant DNA virus and method for preparation thereof
GB2297615B (en) Chemotaxis assay procedure and membrane for use therein
AU1811299A (en) Dental implant system and method
AU3783395A (en) Drug-loaded elastic membrane and method for delivery
AU4767696A (en) Method and system for sterilizing medical instruments
GB9721096D0 (en) Integrated dental chair and post-mounted delivery system
AU1838495A (en) Method for using tobacco mosaic virus to overproduce peptides and proteins
AU4139996A (en) Neisseria meningitidis culture medium for outer membrane protein complex fermentation
AU3822199A (en) Basb013 dna and proteins from neisseria meningitidis
EP0934427A4 (en) RH BLOOD GROUP ANTIQUE COMPOSITIONS AND METHOD FOR USE THEREOF
AU2870297A (en) Gas capsule and gas delivery system
AU5175798A (en) Membrane and methods of preparing and using same
AU3636195A (en) Support post for use in dental implant system
ZA977402B (en) A DNA and a method of preparing a protein thereby
NO951750L (no) Renset "nontypable" Haemophilus influenzae P5 protein som en vaksine for "nontypable" Haemophilus influenzae stamme
AU2471795A (en) Azlactone-functional membranes and methods of preparing and using same
DE69624128D1 (de) Inhibierende und nichtinhibierende antigenbindende polypeptide gegen menschliche p450 enzyme
AU2901997A (en) Immunogenic complex, use, method of preparation thereof and vaccine containing same
AU5981496A (en) Cell-cycle regulatory proteins from human pathogens, and use s related thereto
AU5707498A (en) Novel human membrane protein
GB9523497D0 (en) Cell membrane protein and application thereof